| 期刊簡介 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Journal of Cachexia Sarcopenia and Muscle LetPub Score 8.5
50 ratings
Rate
Reputation 9.4 Influence 8.1 Speed 7.2 | ||||||||||||||||||||
| 期刊簡稱 | J CACHEXIA SARCOPENI | ||||||||||||||||||||
| ISSN | 2190-5991 | ||||||||||||||||||||
| E-ISSN | 2190-6009 | ||||||||||||||||||||
| h-index | 48 | ||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||
| 自引率 (2023-2024) | 8.50%自引率趨勢 | ||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||
| 官方網站 | https://onlinelibrary.wiley.com/journal/1353921906009 | ||||||||||||||||||||
| 在線稿件提交 | https://www.editorialmanager.com/jcsm/ | ||||||||||||||||||||
| 開放訪問 | Yes | ||||||||||||||||||||
| 出版商 | WILEY | ||||||||||||||||||||
| 主題領域 | MEDICINE, GENERAL & INTERNAL | ||||||||||||||||||||
| 出版國/地區 | GERMANY | ||||||||||||||||||||
| 發行頻率 | 四半期刊行 | ||||||||||||||||||||
| 創刊年 | 2010 | ||||||||||||||||||||
| 每年文章數 | 318每年文章數趨勢 | ||||||||||||||||||||
| 黃金OA百分比 | 100.00% | ||||||||||||||||||||
OA Related Info![]() | APC: Yes( EUR3920; GBP3120; USD4910; ) APC waiver:Check Notes Other charges: No Keywords: cachexia、sarcopenia、muscle、muscle wasting、wasting syndromes、body composition Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||
| Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2190-5991%5BISSN%5D | ||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 16 Weeks | ||||||||||||||||||||
| 競爭力 * | 來自作者的數據: | ||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||
| *所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Journal of Cachexia Sarcopenia and Muscle] 的評論 | 撰寫評論 |
| 作者: lixmdxx 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2026-07-03 10:16:19 評論於 Submitted in November 25th, 2025, accepted after revision in July 26th, 2026. |
| 作者: 用户9057 領域: 医学 審稿時間: 6.0 month(s) 結果: 修改後接受 撰寫評論 |
2025-11-27 14:45:23 評論於 24.12 Submit 25.5 Revise 25.7 Resubmit 25.11 Accept I feel that the efficiency of the magazine is slow. |
| 作者: Allewen 領域: 医学 審稿時間: 8.0 month(s) 結果: 直接被接受 撰寫評論 |
2025-09-12 23:41:26 評論於 How long does it usually take from acceptance to publication? |
| 作者: Allewen 領域: 医学 審稿時間: 8.0 month(s) 結果: 直接被接受 撰寫評論 |
2025-09-12 23:39:30 評論於 How long have you been publishing? It's been over a month since accept. |
| 作者: 用户9057 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2025-08-31 13:37:10 評論於 I spent a month in DIP. |
| 作者: lll1235 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2025-07-09 11:36:45 評論於 How many days has it been since RRC? OP, please let me know, I have been in RRC for almost 2 months. |
| 作者: 用户9057 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2025-06-25 11:52:47 評論於 Gave me two months for repair. |
| 作者: lll1235 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2025-06-17 17:04:12 評論於 Has the original poster responded yet? I haven't heard anything about the post made in February. |
| 作者: 用户9057 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2025-05-13 20:01:57 評論於 Launched in December of the 24th year, the 20th day of the first round of RRC provides some reference for friends who are considering investing. |
| 作者: iko 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2025-04-20 13:03:14 評論於 Received: 31 May 2024 | Revised: 3 March 2025 | Accepted: 18 March 2025 |
| 作者: 小医 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2025-03-24 09:14:54 評論於 Could you provide a timeline for the submission process? |
| 作者: iko 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2025-03-22 20:32:39 評論於 It has strong specialization, focusing on various myopathy-related diseases. The review process is fast, but the magazine's processing is a bit slow. |
| 作者: mhp 領域: 医学 審稿時間: 2.0 month(s) 結果: 拒稿 撰寫評論 |
2022-06-09 21:59:42 評論於 Two reviewers provided major revision comments, but unexpectedly, the paper was still rejected. It feels like the requirements weren't that high, yet the acceptance rate is low. |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us